Home  /  Resource Library  /  Frontline Ibrutinib/Venetoclax Elicits Durable Responses in CLL With Undetectable MRD

Frontline Ibrutinib/Venetoclax Elicits Durable Responses in CLL With Undetectable MRD

EHA 2021